Imunon, Inc. ((IMNN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Imunon, Inc. is conducting a Phase II study titled Phase II Study Evaluating the Effect of IMNN-001 on Second Look Laparoscopy (SLL) in Combination With Bevacizumab (BEV) and Neoadjuvant Chemotherapy (NACT) in Newly Diagnosed With Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer. The study aims to assess the safety, dosing, efficacy, and biological activity of adding IMNN-001 to a standard chemotherapy regimen with BEV, compared to chemotherapy with BEV alone, in patients with advanced ovarian, fallopian tube, or primary peritoneal cancer.
Intervention/Treatment: The study tests the experimental drug IMNN-001, an IL-12 plasmid formulated with PEG-PEI-Cholesterol lipopolymer, in combination with standard chemotherapy drugs Paclitaxel and Carboplatin, and Bevacizumab, to enhance treatment outcomes.
Study Design: This is a randomized, open-label, multi-center trial with a parallel intervention model. There is no masking involved, and the primary purpose is treatment. Participants are allocated to either the experimental group receiving IMNN-001 with chemotherapy and BEV or the control group receiving only chemotherapy and BEV.
Study Timeline: The study began on February 10, 2023. The primary completion and estimated overall completion dates are not provided, but the last update was submitted on August 12, 2025. These dates are crucial for tracking progress and anticipating results.
Market Implications: The ongoing study could significantly impact Imunon, Inc.’s stock performance and investor sentiment, especially if the results demonstrate enhanced efficacy of IMNN-001. Positive outcomes could position Imunon favorably against competitors in the oncology sector, potentially increasing its market share and investor interest.
The study is currently recruiting, and further details are available on the ClinicalTrials portal.